Hospitals and specialist healthcare units are at the frontline of the battle to detect, manage and control antimicrobial resistance (AMR) among patients and in their clinical environment. While investment in the development of new antibiotics is crucial, another important area where innovation is needed is the rapid detection, management, and control of AMR in the healthcare environment.
RaDAR aims to address this urgent need for rapid detection and effective infection control systems for AMR, through a public procurement of innovation (PPI). Four healthcare buyers have identified an unmet need for rapid detection of multi-drug resistant microorganisms (MDROs) and antimicrobial resistance management and control systems to combat this serious and growing global problem.
The procurement will be carried out in a collaborative manner by the organisations of the buyers' group, GIP Réseau des acheteurs hospitaliers (Resah) will act as lead procurer.
As of the date of the publication of this information notice the RaDAR PPI buyers' group is composed of:
- GIP Resah (France)
- Institut Catala d’Oncologia (Spain)
- Servicio Vasco de Salud Osakidetza (Spain)
- Universitá degli Studi di Napoli Federico II, Department of Public Health (Italy)
It is anticipated that these buyers will launch coordinated tenders for the procurement of innovative solutions to address this challenge in Q3 of 2023.
This prior information notice has been published to provide early notification that a public procurement of innovation will take place and that a period of Open Market Consultation (OMC) is going to be launched.
The first stage of the OMC is a market sounding: Interested parties, market actors and innovation agents are invited to read the market Sounding Prospectus (MSP) and provide feedback via the Market Response Form: https://radar-ppi.com/procurement/
The second stage involves five Open Market Consultation events: These events will be in person and online and you are invited to register for these events via the market response form which can be found at: https://radar-ppi.com/procurement/.
A direct link to the response form can be found at RaDAR Market Response Form
Based on the conclusions of the second stage, a potential third stage of the OMC will be opened to perform bilateral meetings between public buyers and economic operators. In that case, interested parties, market actors and innovation agents will be invited to have bilateral meetings with public buyers after the Open Market Consultation events. Any update on this behalf will be provided in the website https://radar-ppi.com/procurement/
The aim of this open market consultation is to open a dialogue with the supply chain to:
- Explore what solutions are or could be available given the right market conditions to address the unmet needs and requirements identified by the buyers group (see section 3)
Understand the timeframes over which these solutions can be mobilised or become available
- Inform the buyers group as to how we can support suppliers and innovators to deliver innovative solutions to meet these needs.
The buyers and their expert partners have conducted an initial state of the art review and believe that the supply chain has the information, insights and creativity to address the challenges outlined in the MSP, and are open to all ideas, from all parts of the supply chain, that could contribute to addressing this important challenge area.
The feedback from the supply chain will be used to refine the clinical demand of the four buyers and inform the collaborative tender specification and strategy.
RaDAR Buyers Group will conduct a cross-border collaborative procurement of innovation, which means that each buyer will publish their own call for tenders in their country (1 call in France, 1 call in Italy and 2 calls in Spain).